African sleeping sickness is a debilitating and often fatal disease caused by tsetse fly transmitted African trypanosomes. These extracellular protozoan parasites survive in the human bloodstream by virtue of a dense cell surface coat made of variant surface glycoprotein. The parasites have a repertoire of several hundred immunologically distinct variant surface glycoproteins and they evade the host immune response by antigenic variation. All variant surface glycoproteins are anchored to the plasma membrane via glycosylphosphatidylinositol membrane anchors and compounds that inhibit the assembly or transfer of these anchors could have trypanocidal potential. This article compares glycosylphosphatidylinositol biosynthesis in African trypanosomes and mammalian cells and identifies several steps that could be targets for the development of parasite-specific therapeutic agents. ß
Introduction
Sleeping sickness a¡ects millions of people in subSaharan Africa and the WHO estimates that there are currently over 300 000 new cases a year. There are no vaccines and current drugs are relatively toxic and di¤cult to administer. The African trypanosomes are extracellular protozoan parasites that live in the blood, lymph and interstitial £uids of the infected mammalian host where they divide by binary ¢ssion. The ability of the trypanosome population to evade the host immune response is due to a dense and uniform protective coat [1] made of about 10 7 copies/cell of a 55 kDa variant surface glycoprotein (VSG) [2] (Fig. 1 ). This dense palisade of VSG glycoprotein forms a di¡usion barrier that prevents the approach of macromolecules to the parasite plasma membrane and protects the parasite from lysis by the alternative-and lectin-mediated complement pathways. An individual trypanosome expresses only one VSG gene at a time but contains about a thousand VSG genes encoding structurally similar [3] but immunologically distinct VSGs. In natural and experimental infections, the mammalian host mounts a potent humoral immune response to the prevailing population of VSG coats that leads to almost complete clearance of the parasites. However, the switching of VSG genes by some parasites gives rise to a new population that replicates unchecked until another speci¢c immune response is elicited. This process of antigenic variation [4] is repeated until the death of the host.
Depending on the VSG variant, VSG monomers contain one, two or three N-glycosylation sites occupied by oligomannose and/or complex oligosaccharides [5^7] . All VSGs form homodimers anchored to the plasma membrane via glycosylphosphatidylinositol (GPI) membrane anchors (one per VSG monomer) of conserved structure that vary only in the extent of their side chain galactosylation [7] . In contrast to the extremely high density of GPI-anchored glycoproteins in the trypanosome (Fig. 1) , mammalian cells contain mostly transmembrane and peripheral glycoproteins at the cell surface and GPI-anchored proteins are in the minority. To put this into context, one of the most abundant mammalian GPIanchored proteins is rat thymocyte Thy-1 (present at about 6U10 5 copies per cell [8] ) and a piece of membrane like that modelled ( Fig. 1) for the trypanosome would contain less than one molecule of Thy-1. Despite their lower density, mammalian GPI-anchored proteins are clearly vital since GPI knockouts are embryo-lethal in mice and tissue-speci¢c GPI knockout causes signi¢cant tissue-speci¢c defects [9] .
In conclusion, the absolute dependence of the trypanosome on its protective VSG coat, and the dependence of the latter on its GPI anchors, makes the parasite GPI biosynthetic pathway an attractive therapeutic target. However, the presence, and importance, of GPI anchored glycoproteins in mammals suggest that parasite-speci¢c inhibitors of GPI biosynthetic enzymes are desirable. This article focuses on the known and suggested di¡erences between Trypanosoma brucei and mammalian GPI biosynthesis.
GPI biosynthesis
The conserved EtNP-6ManK1-2ManK1-6ManK1-4GlcNK1-6myo-inositol1-P-lipid core region of all protein-linked GPI membrane anchors [10^45] (Fig.  2) suggests conservation in the GPI biosynthetic machinery. The African trypanosome played a key role in the development of methodologies to study GPI biosynthesis. Intact GPI anchor precursors were ¢rst identi¢ed and characterised in T. brucei [46^48] and it was used to develop the ¢rst cell-free system to delineate the GPI biosynthetic pathway [49] . The cell-free system is based on washed membranes primed with UDP-GlcNAc and GDP-[ 3 H]Man in the presence of tunicamycin to suppress the synthesis of dolichol cycle intermediates. The radiolabelled GPI intermediates formed in the membranes from endogenous phosphatidylinositol (PI) are extracted in solvent and analysed by thin-layer chromatography. Enzyme and chemical treatments are then used to assign the chemical structures of the GPI intermediates. This system has been adapted to study GPI biosynthesis in a variety of organisms, including mammalian cells and yeast ([50^54] , and references therein). The essential features of GPI biosynthesis in the bloodstream form of T. brucei [49, 55] and mammalian cells [50, 51] are shown in Fig.  3A ,B.
The UDP-GlcNAc:PI K1-6
N-acetylglucosaminyltransferase complex
The biosynthesis of GPI anchors starts with the transfer of GlcNAc from UDP-GlcNAc to PI [56, 57] on the cytoplasmic face of the ER [58, 59] . In mammalian cells, this simple reaction requires at least four proteins (PIG-A, PIG-C, PIG-H and hGPI-1) that form a complex in the ER membrane (Fig. 3C) [60, 61] . The PIG-A component is most likely the catalytic subunit since it has homology with a bacterial GlcNAc-transferase. Homologues of the PIG-A, PIG-C and hGPI-1 genes (GPI3, GPI2 and GPI1, respectively) exist in the yeast Saccharomyces cerevisiae [62^64] but a PIG-H homologue is missing in that organism.
There is relatively little information on the specif- [7] . The structure of a VSG dimer, based on the N-terminal crystal structure [3] , is shown (bottom right) next to the primary structure of the GPI anchor [11] (bottom left). The boxed section of the GPI anchor structure is conserved throughout the eukaryotes. The galactose side chains and the fatty acids of the PI moiety, both myristate, are unique to VSG. Fig. 2 . GPI anchor structures. All GPI anchors attached to protein contain the conserved structure shown above with various substituents (R1^R7) and lipids, as indicated. Some structures contain an additional fatty acyl chain attached to the 2-position of the myo-inositol ring. All metazoan organisms contain at least one, and sometimes two, extra ethanolamine phosphate (EtNP) substituents in addition to the one used as a bridge to the protein C-terminal amino acid. When a substituent is known to be attached to a certain sugar residue but the linkage position is unknown, this is indicated by a question mark. Square brackets are used to show substituents for which the site of attachment has not been determined. The þ symbol indicates that the associated residue is found on only a proportion of the structures. AEP is 2-aminoethylphosphonate.
icity of the GlcNAc-transferase complex, except that (i) the partially puri¢ed mammalian complex prefers bovine PI (i.e. primarily sn-1-stearoyl(C 18:0 )-2-arachidonoyl(C 20:4 )-PI) to soybean PI (i.e. primarily sn-1-palmitoyl(C 16:0 )-2-linoleoyl(C 18:2 )-PI) and to lyso bovine PI (i.e. primarily sn-1-stearoyl-2-lyso-PI) [61] and (ii) the T. brucei enzyme can be inhibited by sulphydryl alkylating agents. The latter inhibition can be blocked by UDP-GlcNAc, suggesting that the key cysteine residue is at, or close to, the sugar donor binding site [65] . There is no information on any of the GlcNAc-transferase components, or the genes encoding them, in T. brucei.
The GlcNAc-PI de-N-acetylase
The GlcNAcK1-6PI intermediate is de-N-acetylated to produce GlcN-PI [56, 57] and this step is a prerequisite for further processing [66, 67] . Rat GlcNAc-PI de-N-acetylase gene has been cloned recently, by complementation of the PIG-L mutant CHO cells, and yeast and human homologues have been identi¢ed [68] . The mammalian de-N-acetylase does not appear to form a complex with the GlcNAc-transferase complex [68] but it is not known whether it associates with other components of the GPI pathway. On the other hand, there is some evidence for substrate channelling between this enzyme and the ¢rst mannosyltransferase in T. brucei [66] , suggesting that the parasite de-N-acetylase and the mannosyltransferases may form a complex.
The GlcNAc-PI de-N-acetylase of T. brucei has been partially puri¢ed and characterised [69] using a series of GlcNAc-PI analogues [70] . That study concluded that: (i) the fatty acid esters assist in the presentation of the GlcNAc-PI substrate to the enzyme, but are not essential for substrate recognition, (ii) a phosphodiester linkage between the myo-inositol and glycerol residues is essential for substrate recognition, (iii) product inhibition by GlcN-PI and acetate is negligible and (iv) D-myo-inositol can be replaced by L-myo-inositol without loss of substrate recognition. Another study examined the substrate speci¢cities of T. brucei and human (HeLa cell) GlcNAc-PI de-N-acetylases with respect to the size of the N-acyl (R) group that can be cleaved from a series of GlcNR-PI substrates and the ability of these enzymes to de-N-acetylate mannosylated GlcNAc-PI intermediates [67] . It was concluded that: (i) the trypanosomal and human enzymes are active on GlcNR-PI substrates where R is acetyl or propionyl but much less active on substrates where R is butyryl, isobutyryl, pentanoyl or hexanoyl and (ii) mannosylated GlcNAc-PI structures are not substrates for the trypanosomal or human de-N-acetylases, demonstrating that de-N-acetylation must precede mannosylation in GPI biosynthesis. A further study examined the abilities of the human and parasite enzymes to act on substrates with O-alkyl substituents attached to position 2 of the D-myo-inositol residue and their stereospeci¢cities towards the myo-inositol residue [71] . The results showed that the human enzyme is more fastidious than the parasite enzyme on both counts. Thus, whereas the trypanosomal enzyme turned over all three of the substrate analogues investigated (i.e. GlcNAc-(2-O-methyl)PI, GlcNAc-(2-O-octyl)PI and GlcNAc-P(L)I), albeit at lower rates than for GlcNAc-PI, the human enzyme acted only on GlcNAc-(2-O-methyl)PI at a detectable rate. These di¡erences in the substrate speci¢c-ities of the trypanosomal and human GlcNAc-PI de-N-acetylases suggest that it may be possible to design or discover parasite-speci¢c de-N-acetylase inhibitors with therapeutic potential.
The Dol-P-Man:GlcN-PI/GlcN-(acyl)PI K1-4 mannosyltransferase (MT-I)
One major di¡erence between the parasite and mammalian pathways is the relative order of inositol acylation and mannosylation of GlcN-PI. T. brucei strictly mannosylates GlcN-PI to Man 1 GlcN-PI prior to inositol acylation [55, 72] whereas the reverse is true for the mammalian pathway [57, 72, 73 ] (see Fig.  3A ,B and Fig. 4) . The Dol-P-Man donor requirement of the ¢rst mannosyltransferase (MT-I), and the subsequent mannosyltransferases, has been demonstrated in T. brucei [74] but none of the proteins or genes associated with the ¢rst or second mannosylation reactions have been identi¢ed in any organism.
The apparent di¡erence in the substrate speci¢city of the parasite and host MT-I enzymes, requiring GlcN-PI and GlcN-(acyl)PI as acceptor substrates, respectively (Fig. 4) , has been investigated using cell-free systems and a series of synthetic GlcN-PI analogues with O-alkyl substituents attached to posi-tion 2 of the D-myo-inositol residue. The ¢rst of these, GlcN-(2-O-methyl)PI [75] , was shown to be a good substrate for T. brucei MT-I but neither a substrate nor an inhibitor of HeLa cell MT-I [72] . The identi¢cation of a selective substrate for T. brucei MT-I suggested that parasite-speci¢c inhibitors should also be attainable. This prediction was con¢rmed recently when GlcN-(2-O-octyl)PI and GlcN-(2-O-hexadecyl)PI were tested and found to be parasite-speci¢c GPI pathway inhibitors with di¡erent modes of action: GlcN-(2-O-hexadecyl)PI inhibits T. brucei MT-I while GlcN-(2-O-octyl)PI inhibits the T. brucei inositol acyltransferase [76] (Fig. 4) . Although these compounds are unlikely to work in vivo, since they will probably not pass through the plasma membrane, the existence of parasite-speci¢c inhibitors that are active in vitro is encouraging and features of these compounds are being combined with other information on the ¢ne speci¢city of T. brucei MT-I [66] to design smaller and less polar inhibitors.
Inositol acyltransferases and inositol deacylases
The role of inositol acylation (i.e., the esteri¢cation of the hydroxyl group at the 2-position of the D-myoinositol residue with a fatty acid, most often palmitic acid [41,77^79] (Fig. 2) ) in GPI biosynthesis is largely unknown. It is not an essential step in all organisms since, for example, the Leishmania do not appear to perform this reaction [80, 81] . Furthermore, in many cases (Fig. 2 ) the ¢nal protein-linked GPI anchor is not inositol acylated. Nevertheless, in mammalian cells and in yeast, most of the GPI intermediates are inositol acylated [50^54] and in many mammalian cells, and in yeast, the fatty acid is removed from the inositol residue immediately after transfer of the mature GPI precursor to protein in the ER [82, 83] .
The timing, nature and role of inositol acylation and inositol deacylation in T. brucei appears to be quite unique. Thus, as noted above, whereas inositol acylation of GlcN-PI precedes mannosylation in mammalian cells [57, 72, 73] and in yeast [52] it only occurs after the action of MT-I in T. brucei [55, 72] . Furthermore, (i) inositol acylation is CoA and/or acyl-CoA dependent in mammalian cells [73, 84] and yeast [52] , but independent of these cofactors in T. brucei [49, 55] ; (ii) inositol acylation is inhibited by phenylmethylsulphonyl £uoride (PMSF) in T. brucei, but not in mammalian cells [85] ; (iii) the fatty acids transferred to inositol are more heterogeneous in T. brucei than they are in mammalian cells [86] and (iv) most of the GPI intermediates in bloodstream forms of T. brucei are in a dynamic equilibrium between inositol acylated and inositol deacylated forms (Fig.  3A) via the actions of a PMSF-sensitive inositol acyltransferase [85] and a diisopropyl£uorophosphate (DFP)-sensitive inositol deacylase [55] . The ability to manipulate the acylation status of GPI intermediates in T. brucei with PMSF and DFP has shown that, in that organism, inositol acylation is necessary for e¤cient addition of the ethanolamine phosphate bridge and that subsequent inositol deacylation is essential for the fatty acid remodelling reactions [55, 85] (see Fig. 3A ). The former point was con¢rmed in the study with GlcN-(2-O-methyl)PI which was e¤ciently converted to Man 3 GlcN-(2-O-methyl)-PI by the cell-free system but which failed to receive the ethanolamine phosphate bridge [72] . Given the importance of GPI fatty acid remodelling for T. brucei (see below) and the essential nature of the ethanolamine phosphate bridge for GPI addition to protein, both the T. brucei inositol acyltransferase and the inositol deacylase are potential therapeutic targets.
The Dol-P-Man:Man 1 GlcN-( þ acyl)PI K1-6 mannosyltransferase (MT-II)
Essentially nothing is known about the proteins or [55] , and references therein, and [50, 51] , and references therein. The di¡erences in the order of mannosylation by the ¢rst K-mannosyltransferase (MT-I) and inositol acylation by inositol acyltransferase (Acyl-T) and the di¡er-ence in the timing of inositol deacylation by inositol deacylase (Ino de-Ac) are highlighted. Other signi¢cant di¡erences include the addition of an extra ethanolamine phosphate group to the ¢rst Man residue in the mammalian pathway and the nature of the side chain carbohydrate modi¢cations that occur after GPI addition to protein. The topology [58, 59] and known complexation, see text, of the components of the mammalian GPI biosynthetic pathway are summarised in C.
genes involved in this step of the pathway in any organism.
The Dol-P-Man:Man 2 GlcN-( þ acyl)PI K1-2 mannosyltransferase (MT-III)
A gene (PIG-B) encoding a protein with homology to a yeast K-mannosyltransferase was cloned [87] by complementation of a murine thymoma mutant de¢cient in adding the third KMan residue to GPI intermediates [51] . The PIG-B gene is believed to encode MT-III and a yeast homologue (GPI10) has been identi¢ed and shown to be essential for GPI biosynthesis in yeast [53, 54] . Expression of human PIG-B cDNA rescued a GPI10 3 conditional mutant under non-permissive conditions and restored GPI biosynthesis, showing that the two genes are functional homologues [54] . BLAST searches have also revealed a T. brucei PIG-B homologue but there are no functional data on this gene. The PIG-B gene product is predicted to span the ER membrane seven or nine times, which is a similar topology to other ER resident glycosyltransferases [88] and di¡er-ent from the type-2 membrane protein structure typical of Golgi glycosyltransferases.
MT-III activity has been detected in the T. brucei cell-free system using the simple glycoside ManK1-6ManK1-O-(CH 2 ) 7 CH 3 as an exogenous acceptor [89] and the mechanism of the inhibition of GPI biosynthesis by mannosamine [90, 91] has been studied in that organism [92] . Essentially, mannosamine is incorporated in GDP-Man and Dol-PMan and then into GPI intermediates to produce ManNH 2 ManGlcN-PI. The latter has an amino group in place of the hydroxyl acceptor site for MT-III, and therefore cannot act as an acceptor, and appears to inhibit the action of MT-III on endogenous Man 2 GlcN-PI intermediates [92] . Unfortunately, the e¡ects of mannosamine are not speci¢c to trypanosomes and, because trypanosomes synthesise an excess of GPI precursors [92, 93] , the addition of GPI anchors to VSG is not prevented by mannosamine.
Ethanolamine phosphotransferases
All GPI anchors utilise an ethanolamine phosphate (EtNP) bridge between the third Man residue and the COOH-terminal amino acid of the GPIanchored protein (except for a small proportion of Trypanosoma cruzi anchors that utilise the EtNP analogue 2-aminoethylphosphonate [20] ). The origin of this EtNP group has been shown to be the phospholipid phosphatidylethanolamine (PE) in yeast [94] and in T. brucei [95] . A mammalian gene (PIG-F) required for the addition of the EtNP bridge has been cloned by complementation but it is not known whether this encodes the transferase itself or an essential accessory element [96] .
T. brucei, and many other protozoan organisms such as Leishmania and Plasmodium falciparum, do not express additional EtNP groups on the ¢rst and second Man residues of the conserved GPI core. In contrast, many other organisms express EtNP on the ¢rst Man residue and on some proportion of the second Man residue (Fig. 2) . It has recently come to light that these additional EtNP groups are also added during GPI biosynthesis in yeast [53, 54] . This has stimulated a reinterpretation [54] of the activity of the terpenoid lactone compound YW3548, a potent inhibitor of GPI biosynthesis in mammalian cells and yeast but not in P. falciparum or T. brucei [97] . Thus, it is possible that the accumulation of Man 2 GlcN-(acyl)PI in yeast treated with YW3548 is due to the inhibition of EtNP addition to the ¢rst Man residue rather than direct inhibition of MT-III. This model assumes that yeast and mammalian MT-III require the presence of the EtNP group on the ¢rst Man residue for substrate recognition [54] whereas T. brucei MT-III does not; a di¡erence that may be exploitable for the inhibition of trypanosome MT-III. In any case, the selective inhibition of GPI biosynthesis in yeast and mammalian cells by YW3548 [97] is another indication of fundamental di¡erences between parasite and mammalian/yeast GPI biosynthesis.
Other GPI glycosyltransferases
The presence of additional Man residues in GPI anchors is quite common (Fig. 2) . In yeast, a fourth Man residue is added to the GPI precursor before transfer to protein [82] and the ¢fth Man residue (that can be either K1-2 or K1-3 linked) is added in the Golgi apparatus [98] . The origin of the fourth Man residue in mammalian cells is less clear and it may be added before or after GPI transfer to the protein. The signi¢cance of the additional Man residues is yet to be reported. Additional carbohydrate side chains are quite common in mammalian cells, e.g. the addition of GalNAc and/or GalL1-3GalNAc in L1-4 linkage to the ¢rst Man residue (Fig. 2) . There is no information on the glycosyltransferases responsible for these modi¢cations.
The GPI anchors on T. brucei VSG can be modi¢ed with several Gal residues ( Figs. 1 and 2) . The proteins and genes responsible for these modi¢ca-tions have not been identi¢ed but the activities of two of them, the UDP-Gal:Man 3 GlcN-PI K1-3 galactosyltransferase [99, 100] and the UDP-Gal: Gal 1 Man 3 GlcN-PI K1-2 galactosyltransferase [101] , can be detected using the exogenous glycoside substrates ManK1-2ManK1-S-(CH 2 ) 7 CH 3 and ManK1-2(GalK1-3)ManK1-O-(CH 2 ) 7 CH 3 , respectively. The K-and L-galactosyltransferases that add Gal residues directly to the trimannosyl core appear to be located in the ER [11, 102] while the others are most likely in the Golgi apparatus [11, 103] .
The VSGs can be classi¢ed into four classes based on COOH-terminal sequence homology [104] . Most VSG variants belong to class-1 and class-2 and only one class-4 variant and two class-3 variants are known. The mean Gal content of the GPI glycans of class-1 VSGs is 3.1 residues per mol GPI [10] whereas this ¢gure is about 4.9 residues per mol for the class-2 VSG [11] and the class-3 VSGs do not contain any Gal [105] . These di¡erences in GPI anchor galactosylation appear to re£ect steric constraints imposed by the VSG COOH-terminal structure on galactosyltransferase activity. This conclusion is consistent with the original suggestion [106] that GPI anchor galactosylation, that is unique to African trypanosomes, is a mechanism for ¢lling space close to the plasma membrane beneath and around the VSG COOH-terminus. This processing may be important in maintaining a functional protective barrier on the surface of the parasite regardless of which VSG variant is being expressed. Since the GPI-modifying galactosyltransferases are unique to the African trypanosomes, and since the repertoire of non-galactosylated class-3 VSG variants is so small, these enzymes could be considered potential therapeutic targets.
GPI lipid remodelling
Lipid exchange occurs in yeast where diacylglycerol is exchanged for ceramide in the ER and where this ceramide can be exchanged for another ceramide in the Golgi [82, 107, 108] . Furthermore, the presence of exclusively distearoyl-PI in some mammalian GPI anchors (e.g., porcine membrane dipeptidase and human CD52-I [38, 41] ) suggests that lipid remodelling may also occur in some mammalian tissues. The trypanosome VSG GPI anchors contain exclusively myristic (C 14:0 ) acid in the form of dimyristoylglycerol [10] and lipid remodelling of GPI anchors was ¢rst described in this organism [109] . The GPI intermediates in T. brucei are based on sn-1-stearoyl-2-acyl-PI (where the acyl group at the sn-2 position is a mixture [110] ) up until the fatty acid remodelling steps when the fatty acids are sequentially removed and replaced by myristate (Fig. 3A) . The trypanosome also performs proofreading myristate exchange reactions on the GPI precursor [111] and on the VSGlinked mature GPI anchor [112] to ensure the exclusivity of dimyristoylglycerol in the VSG anchor. This type of myristate-speci¢c fatty acid remodelling has been reported in Leishmania GPIs, where longer chain fatty acids in the sn-2 position of sn-1-alkyl-2-acyl-PI are replaced by myristate [81] , but not in mammalian cells. The need for myristate in the VSG anchor remains obscure but myristate analogues that become incorporated into the VSG anchor are toxic to trypanosomes [113, 114] . Thus, the enzymes of fatty acid remodelling/myristate exchange and the other trypanosome systems required for scavenging myristate [115] are possible targets for anti-trypanosome chemotherapy.
The GPI-transamidase complex
The transfer of the mature GPI precursor to protein involves a transamidation reaction whereby a COOH-terminal GPI addition signal peptide (typically 17^35 amino acids in length) is directly replaced by the formation of an amide linkage to the amino group of the ethanolamine phosphate bridge [116, 117] . In yeast the transamidase is made of at least two components encoded by the GAA1 and GPI8 genes [118, 119] . The latter gene, which has homology with some plant endopeptidases, is believed to encode the catalytic subunit while data presented by Kinoshita and colleagues (unpublished work) suggest that GAA1 encodes a subunit that is involved in recognising the site of GPI addition in the protein precursor. Species-speci¢c di¡erences in GPI-transamidase speci¢city have been noted from site-directed mutagenesis studies at and around the transamidation (g) site [116, 120] . For example, Cys is a poor g amino acid in yeast but an acceptable residue in mammalian cells. The g+1 and g+2 residues (i.e., the amino terminal and subterminal residues of the cleaved GPI signal peptide) are also important determinants for GPI-transamidation and these, like the g amino acid, are generally relatively small residues. Interestingly, the g/g+1/g+2 triplet of T. brucei class-1 VSGs does not function in COS cells, suggesting that there may be exploitable di¡erences between mammalian and parasite GPI-transamidases [121] . Proteins that fail to acquire a GPI anchor are retarded in the ER [122] and degraded by a proteasome-dependent pathway [123, 124] .
Perspectives
Considerable progress has been made on the biochemistry and molecular biology of GPI biosynthesis. Despite the overall conservation of GPI core structure, signi¢cant di¡erences in the substrate speci¢cities of trypanosome and mammalian GPI biosynthetic enzymes have been demonstrated. Thus, the GlcNAc-PI de-N-acetylase, the MT-I and MT-III mannosyltransferases, the inositol acyltransferase, the inositol deacylase, the trypanosome-speci¢c fatty acid remodelling/exchange enzymes, the GPI-transamidase and the trypanosome-speci¢c side chain galactosyltransferases are all potential therapeutic targets. The fact that parasite-speci¢c inhibitors are beginning to emerge is encouraging but the cloning of T. brucei (and other pathogen) GPI pathway genes and structural information on GPI pathway components remain important goals for the future. Finally, many other protozoan parasites, such as T. cruzi, Leishmania, Plasmodium and Toxoplasma, are rich in GPI-anchored glycoproteins and/or GPI-related glycoconjugates. Therefore, GPI pathway inhibitors developed with African trypanosomes may also have therapeutic potential in a number of other diseases.
